Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.59
DNPUF's Cash-to-Debt is ranked lower than
55% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. DNPUF: 1.59 )
Ranked among companies with meaningful Cash-to-Debt only.
DNPUF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: 1.32 Max: No Debt
Current: 1.59
Equity-to-Asset 0.63
DNPUF's Equity-to-Asset is ranked lower than
51% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DNPUF: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
DNPUF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.6 Max: 0.85
Current: 0.63
0.51
0.85
Interest Coverage 72.90
DNPUF's Interest Coverage is ranked lower than
52% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. DNPUF: 72.90 )
Ranked among companies with meaningful Interest Coverage only.
DNPUF' s Interest Coverage Range Over the Past 10 Years
Min: 16.13  Med: 37.62 Max: 421.8
Current: 72.9
16.13
421.8
Piotroski F-Score: 5
Altman Z-Score: 3.43
WACC vs ROIC
4.07%
8.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 12.39
DNPUF's Operating Margin % is ranked higher than
63% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. DNPUF: 12.39 )
Ranked among companies with meaningful Operating Margin % only.
DNPUF' s Operating Margin % Range Over the Past 10 Years
Min: 5.82  Med: 10.02 Max: 17.44
Current: 12.39
5.82
17.44
Net Margin % 7.65
DNPUF's Net Margin % is ranked higher than
55% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. DNPUF: 7.65 )
Ranked among companies with meaningful Net Margin % only.
DNPUF' s Net Margin % Range Over the Past 10 Years
Min: 2.46  Med: 5.65 Max: 9.69
Current: 7.65
2.46
9.69
ROE % 6.92
DNPUF's ROE % is ranked higher than
50% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. DNPUF: 6.92 )
Ranked among companies with meaningful ROE % only.
DNPUF' s ROE % Range Over the Past 10 Years
Min: 2.68  Med: 5.44 Max: 8.21
Current: 6.92
2.68
8.21
ROA % 4.40
DNPUF's ROA % is ranked higher than
55% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. DNPUF: 4.40 )
Ranked among companies with meaningful ROA % only.
DNPUF' s ROA % Range Over the Past 10 Years
Min: 1.5  Med: 3.33 Max: 6.54
Current: 4.4
1.5
6.54
ROC (Joel Greenblatt) % 26.22
DNPUF's ROC (Joel Greenblatt) % is ranked higher than
68% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. DNPUF: 26.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DNPUF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.87  Med: 16.16 Max: 27.95
Current: 26.22
8.87
27.95
3-Year Revenue Growth Rate 5.10
DNPUF's 3-Year Revenue Growth Rate is ranked lower than
52% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. DNPUF: 5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DNPUF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14.4  Med: 4.3 Max: 12.9
Current: 5.1
-14.4
12.9
3-Year EBITDA Growth Rate 3.80
DNPUF's 3-Year EBITDA Growth Rate is ranked lower than
63% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. DNPUF: 3.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DNPUF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -4.4  Med: 2.1 Max: 10.2
Current: 3.8
-4.4
10.2
3-Year EPS without NRI Growth Rate 35.00
DNPUF's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. DNPUF: 35.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DNPUF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.4  Med: -2.5 Max: 35
Current: 35
-24.4
35
GuruFocus has detected 3 Warning Signs with Sumitomo Dainippon Pharma Co Ltd $DNPUF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DNPUF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with DNPUF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:IPSEY, OTCPK:HKMPY, NYSE:RDY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, OTCPK:HLUYY, NAS:OPK, NYSE:TARO, NYSE:PTHN, OTCPK:SFOSF, NAS:NBIX, OTCPK:STDAF, NAS:MDCO, NYSE:CTLT, OTCPK:INVVY, OTCPK:APNHY, OTCPK:SHPHF, NAS:ENDP, NAS:HZNP » details
Traded in other countries:DPM.Germany, 4506.Japan,
Sumitomo Dainippon Pharma Co., formerly Dainippon Sumitomo Pharma Co Ltd, is engaged in the manufacture, sale, purchase, & import, export of pharmaceuticals, veterinary products, food additives, industrial chemicals, & other chemical products, & others.

Sumitomo Dainippon Pharma Co.

Ratios

vs
industry
vs
history
PE Ratio 25.58
DNPUF's PE Ratio is ranked higher than
55% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. DNPUF: 25.58 )
Ranked among companies with meaningful PE Ratio only.
DNPUF' s PE Ratio Range Over the Past 10 Years
Min: 8.17  Med: 24.67 Max: 75.22
Current: 25.58
8.17
75.22
PE Ratio without NRI 25.58
DNPUF's PE Ratio without NRI is ranked higher than
56% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. DNPUF: 25.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
DNPUF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.17  Med: 24.67 Max: 75.22
Current: 25.58
8.17
75.22
Price-to-Owner-Earnings 41.04
DNPUF's Price-to-Owner-Earnings is ranked lower than
64% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. DNPUF: 41.04 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DNPUF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 19.09  Med: 48.68 Max: 519.18
Current: 41.04
19.09
519.18
PB Ratio 1.67
DNPUF's PB Ratio is ranked higher than
73% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. DNPUF: 1.67 )
Ranked among companies with meaningful PB Ratio only.
DNPUF' s PB Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.14 Max: 2.03
Current: 1.67
0.73
2.03
PS Ratio 1.96
DNPUF's PS Ratio is ranked higher than
65% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. DNPUF: 1.96 )
Ranked among companies with meaningful PS Ratio only.
DNPUF' s PS Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.37 Max: 5.76
Current: 1.96
0.69
5.76
EV-to-EBIT 15.65
DNPUF's EV-to-EBIT is ranked higher than
65% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. DNPUF: 15.65 )
Ranked among companies with meaningful EV-to-EBIT only.
DNPUF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 14.2 Max: 49.8
Current: 15.65
8.4
49.8
EV-to-EBITDA 15.65
DNPUF's EV-to-EBITDA is ranked higher than
54% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. DNPUF: 15.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
DNPUF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 12.9 Max: 49.8
Current: 15.65
4.3
49.8
Current Ratio 1.85
DNPUF's Current Ratio is ranked lower than
62% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. DNPUF: 1.85 )
Ranked among companies with meaningful Current Ratio only.
DNPUF' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 2.67 Max: 5.77
Current: 1.85
1.06
5.77
Quick Ratio 1.51
DNPUF's Quick Ratio is ranked lower than
60% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. DNPUF: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
DNPUF' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.18 Max: 4.68
Current: 1.51
0.84
4.68
Days Inventory 224.37
DNPUF's Days Inventory is ranked lower than
86% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. DNPUF: 224.37 )
Ranked among companies with meaningful Days Inventory only.
DNPUF' s Days Inventory Range Over the Past 10 Years
Min: 163.64  Med: 205.82 Max: 224.37
Current: 224.37
163.64
224.37
Days Payable 129.48
DNPUF's Days Payable is ranked higher than
79% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. DNPUF: 129.48 )
Ranked among companies with meaningful Days Payable only.
DNPUF' s Days Payable Range Over the Past 10 Years
Min: 65.16  Med: 144.47 Max: 173.07
Current: 129.48
65.16
173.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.99
DNPUF's Dividend Yield % is ranked lower than
71% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. DNPUF: 0.99 )
Ranked among companies with meaningful Dividend Yield % only.
DNPUF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.86  Med: 1.43 Max: 2.68
Current: 0.99
0.86
2.68
Dividend Payout Ratio 0.23
DNPUF's Dividend Payout Ratio is ranked higher than
71% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. DNPUF: 0.23 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DNPUF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.18  Med: 0.36 Max: 0.83
Current: 0.23
0.18
0.83
Forward Dividend Yield % 103.03
DNPUF's Forward Dividend Yield % is ranked higher than
100% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. DNPUF: 103.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.03
DNPUF's 5-Year Yield-on-Cost % is ranked lower than
74% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. DNPUF: 1.03 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DNPUF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.89  Med: 1.48 Max: 2.78
Current: 1.03
0.89
2.78

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.89
DNPUF's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DNPUF: 6.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DNPUF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.65  Med: 4.58 Max: 79.28
Current: 6.89
1.65
79.28
Price-to-Tangible-Book 3.35
DNPUF's Price-to-Tangible-Book is ranked higher than
54% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. DNPUF: 3.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DNPUF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 1.89 Max: 3.44
Current: 3.35
1.02
3.44
Price-to-Intrinsic-Value-Projected-FCF 1.86
DNPUF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
62% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. DNPUF: 1.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DNPUF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.18 Max: 1.97
Current: 1.86
0.94
1.97
Price-to-Median-PS-Value 1.43
DNPUF's Price-to-Median-PS-Value is ranked lower than
69% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. DNPUF: 1.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DNPUF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1 Max: 3.91
Current: 1.43
0.58
3.91
Price-to-Peter-Lynch-Fair-Value 1.28
DNPUF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
60% of the 168 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. DNPUF: 1.28 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DNPUF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.28  Med: 3.82 Max: 9.93
Current: 1.28
1.28
9.93
Price-to-Graham-Number 1.95
DNPUF's Price-to-Graham-Number is ranked higher than
57% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. DNPUF: 1.95 )
Ranked among companies with meaningful Price-to-Graham-Number only.
DNPUF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.61  Med: 1.5 Max: 3.26
Current: 1.95
0.61
3.26
Earnings Yield (Greenblatt) % 6.40
DNPUF's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. DNPUF: 6.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DNPUF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 7 Max: 11.9
Current: 6.4
2
11.9
Forward Rate of Return (Yacktman) % 19.92
DNPUF's Forward Rate of Return (Yacktman) % is ranked higher than
71% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. DNPUF: 19.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DNPUF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.5  Med: -8.75 Max: 19.92
Current: 19.92
-18.5
19.92

More Statistics

Revenue (TTM) (Mil) $3,712
EPS (TTM) $ 0.70
Beta-0.28
Short Percentage of Float0.00%
52-Week Range $10.85 - 19.20
Shares Outstanding (Mil)397.30
» More Articles for DNPUF.PK

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)